RESEARCH BOARD / COMPARISON
Sermorelin vs Tesamorelin: GHRH Analogs Compared
Two members of the same family — the native short-acting fragment and its stabilized, longer-lasting relative — and where the evidence concentrates for each.
The gist
Sermorelin vs tesamorelin is a comparison within one family. Both are GHRH analogs — synthetic versions of the brain's "make growth hormone" signal — and both prompt the pituitary to release the body's own GH. The difference is durability: sermorelin is the native GHRH(1-29) fragment that clears the blood in about 10-12 minutes [3], while tesamorelin is a stabilized, longer-acting analog engineered to last [11]. That extra duration is part of why tesamorelin, not sermorelin, carries most of the body-composition evidence [7]. If you remember one thing from this page, make it that: same family and same receptor, but the fat-loss numbers people quote almost always come from the longer-acting cousin, not from sermorelin itself.
Same family, different durability
Sermorelin is GHRH(1-29): the short, fully active N-terminal fragment of natural GHRH, rapidly eliminated with a plasma half-life on the order of ~10-12 minutes, though a single dose keeps GH elevated for roughly 3 hours [3]. Tesamorelin is a stabilized synthetic GHRH analog reviewed as a growth-hormone-releasing factor analogue for HIV-associated lipodystrophy [11]. The native fragment's brevity is exactly what motivated stabilized analogs — structural strategies such as a D-Ala2 substitution and serum-albumin-binding chemistry extend a peptide's half-life and reduce clearance [11]. Both act at the same GHRH receptor and preserve the pulsatile, feedback-regulated character of GH release [4][15].
The practical consequence of that durability gap is dosing cadence and exposure. A short-acting fragment delivers a pulse and clears; a stabilized analog sustains a GHRH signal far longer, which changes how the axis is engaged over a day. This is why the two molecules, despite sharing a receptor and a mechanism, accumulated different clinical datasets — the longer-acting analog was the one carried into multi-week body-composition and cognition trials [6][7]. Same family, same target, different pharmacokinetics, and as a result, different evidence.
Where the evidence concentrates
The two molecules' datasets differ. Sermorelin's strongest human evidence is its historical pediatric GH-deficiency efficacy — first-year height velocity rising from ~4.1 to ~7-8 cm/year [1] — and the 14-day GH/IGF-1 reversal in older men [2]. Tesamorelin carries the body-composition record: significant visceral-fat reduction versus placebo in HIV-associated fat accumulation [7], metabolic and body-composition effects in obese adults with reduced GH secretion [9], and the SMART-trial cognition-and-body-fat result in older adults [6]. When a "sermorelin for fat loss" claim cites visceral-fat data, that data usually belongs to tesamorelin — a distinction this comparison keeps explicit. An editorial frames sermorelin's appeal as a physiologic secretagogue that preserves the body's own pulsatile GH release, an argument about mechanism rather than about superior body-composition outcomes [4].
How does sermorelin compare to CJC-1295?
Both are GHRH analogs, but sermorelin is the native, short-lived 1-29 sequence (~10-12 min plasma half-life) [3], whereas longer-acting analogs are engineered to persist. The structure-activity basis is the same family of strategies that extends duration — a D-Ala2 substitution and serum-albumin-binding (DAC) chemistry that prolong half-life and reduce clearance [11]. The practical contrast is duration of action at the same receptor, not a different mechanism.
Sermorelin vs ipamorelin: what is the difference?
They act on different receptors. Sermorelin is a GHRH analog working at the GHRH receptor; ipamorelin is a growth-hormone-releasing peptide (GHRP) acting on the ghrelin/GHS receptor [15]. The two mechanisms are complementary — separate pathways onto the same somatotroph — which is why GHRH analogs and GHRPs are sometimes studied together rather than as substitutes.
How does sermorelin differ from direct HGH injections?
Direct HGH supplies growth hormone from outside and can override the body's feedback; sermorelin instead prompts the pituitary to make its own GH, preserving pulsatility and somatostatin/IGF-1 feedback [4][15]. An editorial argues this is a more physiologic approach to adult-onset growth hormone insufficiency, because the axis keeps governing itself rather than being bypassed [4].
Physiologic by design, but not unregulated
The recurring theme across these comparisons is that GHRH(1-29) and its relatives work with the somatotropic axis rather than around it. Because the IGF-1 rise in the GHRH-analog SMART trial stayed within the physiologic range [6], and because GHRH(1-29) in older men brought GH/IGF-1 toward — not past — youthful levels [2], the class is often described as physiologic. That framing should not be mistaken for "unregulated by anyone." Growth-hormone secretagogues, including GHRH analogs, are prohibited in sport by WADA, and dedicated detection methods exist for them. "Physiologic mechanism" is a statement about how the molecule acts on the pituitary; it is not a statement about legal status in competition, and it is not a clearance for human use outside research.
Which one the studies actually used
A practical reading rule closes the comparison: when a result involves visceral fat, percent body fat, HIV-associated lipodystrophy, or a 20-week cognition endpoint, the molecule under study is the stabilized analog tesamorelin [6][7][9][11]. When a result involves first-year height velocity in children or a 14-day GH/IGF-1 shift in older men, the molecule is GHRH(1-29) itself [1][2]. Pharmacokinetic facts — the ~10-12 minute plasma half-life with GH elevated ~3 hours, and the dose-response across intravenous, subcutaneous, and intranasal routes — were established with the native fragment and its close analog [3][14]. Keeping that map in view is the surest way to read "sermorelin" claims without inheriting tesamorelin's evidence by accident.